Last mentioned: Jul 16, 2026
Across the most recent 12 stories covering FDA — 25% positive, 75% neutral sentiment, averaging 5.6/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Clinical Data Release
Early data for FSHD and DM1 therapies reported by STAT and Endpoints News.
Options Surge
Traders purchase large volumes of call options following the clinical updates.
Price Target Update
Brokerages adjust targets, including a raise to $9.00 by some analysts.
BofA Target Increase
Bank of America raises price target based on pharmaceutical and MedTech pipeline strength.
Q4 2025 Earnings
Both Mineralys and Vuzix report year-end financial results and 2026 guidance.
Institutional Rebalancing
Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
FDA NDA Acceptance
FDA formally accepts Mineralys Therapeutics' application for Lorundrostat.
Fast-Track Approval
FDA approves Tecvayli-Darzalex combination for blood cancer treatment.
FDA Approval & 12-Month High
JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak.
Q4 2025 Earnings
Company reports results and provides 2026 guidance, signaling continued remediation efforts.
FDA U-Turn
Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
Public Dispute
Moderna and administration officials engage in a public disagreement over the regulatory path forward.
Initial Rejection
Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.
Financial Results
Sarepta files results of operations and financial condition with the SEC.
Projected Restart
Target window for the commercial re-launch of SurgiMend and PriMatrix products.
PDUFA Goal Date
Expected timeframe for the FDA's final decision on Lorundrostat commercialization.
New Leadership
Mojdeh Poul assumes role as CEO to lead the company's quality and operational turnaround.
Boston Recall
Integra initiates voluntary recall of all products manufactured in Boston due to endotoxin concerns.
A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Traders have flooded Sarepta Therapeutics with call options following positive early-stage data for its RNA-based rare disease therapies. This surge in bullish sentiment suggests high market confidence in the company's clinical pipeline expansion beyond its core Duchenne muscular dystrophy franchise.
Kestra Medical (KMTS) delivered a strong Q3 2026 performance, highlighted by a 63% year-over-year revenue increase and the ninth consecutive quarter of gross margin expansion. While net losses widened to $34.2 million due to aggressive sales force expansion, the company secured critical access to the VA Federal Supply Schedule and expanded its Florida Medicaid footprint.
LivePerson, Inovio, and Bakkt reported Q4 2025 results highlighting strategic transitions toward AI integration, regulatory milestones, and balance sheet restructuring. While LivePerson capitalizes on generative AI adoption and Inovio nears a critical FDA PDUFA date, Bakkt has streamlined its capital structure to focus on institutional crypto services.
Abeona Therapeutics and Consolidated Water are preparing to report full-year 2025 financial results, highlighting contrasting paths in the biotech and utility sectors. While Abeona faces critical regulatory milestones for its gene therapy pipeline, Consolidated Water continues to leverage infrastructure expansion to drive steady revenue growth.
Josh Brown argues that biotech growth stocks are uniquely positioned to withstand the disruption risks currently de-rating the software and services sectors. By leveraging AI to accelerate discovery while maintaining regulatory and patent moats, the sector offers a rare combination of high growth and structural stability.
Mineralys Therapeutics secured a major regulatory win with FDA acceptance of its Lorundrostat NDA, while Vuzix continues to navigate the transition from pilot programs to enterprise-scale AR deployments.
Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.
The biotech sector experienced a week of high-stakes regulatory and clinical developments, headlined by a key FDA approval for Ascendis Pharma. Meanwhile, Aardvark Therapeutics faced a setback with its HERO trial on hold, and Theravance Biopharma announced strategic job cuts to preserve capital.
Integra LifeSciences (IART) shares faced downward pressure following its Q4 2025 earnings call, as management detailed an extended timeline for its Boston facility restart and the ongoing costs of its Quality Excellence Program. While the company provided its first full-year 2026 guidance, investor caution remains high regarding the path to normalized growth and product re-launches.
The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
Source: news8000.com · wlfi.com
The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
This page surfaces every story mentioning FDA across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |